On January 2, 2025, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Merck's Winrevair (sotatercept). The therapy is approved for adult patients with pulmonary arterial hypertension (PAH).
Winrevair is to be used in combination with other medicines to treat PAH in adults with moderate or marked physical activity limitations, aiming to improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration.
This approval in a major European market expands the commercial potential for Winrevair, a key growth driver for Merck. It provides a new treatment option for PAH patients in the UK, reinforcing Merck's cardiovascular portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.